- NCIt
- C4407
Loading cancer entity…
Loading cancer entity…
Clinical trials
46 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02834013 | Nivolumab and Ipilimumab in Treating Patients With Rare Tumors | active not recruiting | Phase 2 | 798 | National Cancer Institute (NCI)NIH | 2 | Jun 17, 2026 | clinicaltrials |
| NCT04895735 | MC200708 Pemetrexed and Pembrolizumab for the Treatment of Recurrent and/or Metastatic Salivary Gland Cancer | active not recruiting | Phase 2 | 45 | Mayo ClinicOTHER | 1 | Jun 4, 2026 | clinicaltrials |
| NCT02628067 |
| Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-158/KEYNOTE-158) |
| active not recruiting |
| Phase 2 |
| 1,609 |
| Merck Sharp & Dohme LLCINDUSTRY |
| 0 |
| Sep 22, 2025 |
| clinicaltrials |
Data updated 22 days agoSource updated Jun 17, 2026source: clinicaltrials